Status:
COMPLETED
Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms
Lead Sponsor:
Shire
Conditions:
Schizophrenia and Predominant Negative Symptoms
Eligibility:
All Genders
18-55 years
Phase:
PHASE2
Brief Summary
To explore the efficacy of SPD489, as adjunctive therapy to a stable dose of atypical antipsychotic medication, on negative symptoms in adult subjects with clinically stable schizophrenia and predomin...
Eligibility Criteria
Inclusion
- Adults aged 18-55
- Clinically stable Schizophrenia and predominant negative symptoms
- Taking a stable dose of antipsychotic medication
Exclusion
- Clinically notable positive symptoms defined by PANSS
Key Trial Info
Start Date :
September 14 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 20 2011
Estimated Enrollment :
92 Patients enrolled
Trial Details
Trial ID
NCT00922272
Start Date
September 14 2009
End Date
January 20 2011
Last Update
June 9 2021
Active Locations (27)
Enter a location and click search to find clinical trials sorted by distance.
1
K&S Professional Research Services
Little Rock, Arkansas, United States, 72201
2
South Coast Clinical Trials
Anaheim, California, United States, 92804
3
Omega Clinical Trials
Anaheim, California, United States, 92805
4
Clinical Innovations
Costa Mesa, California, United States, 92626